Cardiac Hypertrophy Gene-Edited Cell Models for Drug Discovery

Cardiac hypertrophy is a maladaptive response to chronic pressure or volume overload, affecting an estimated 1 in 500 individuals globally (WHO, 2023). It is a major risk factor for heart failure, which accounts for approximately 17.9 million deaths annually worldwide (WHO, 2023). In the United States, the prevalence of hypertrophic cardiomyopathy (HCM) is about 1 in 200 to 1 in 500 (NCI, 2023). Key risk factors include hypertension, aortic stenosis, obesity, and genetic mutations (e.g., sarcomere protein genes). The 5-year survival rate for patients with symptomatic heart failure is approximately 50% (NCI, 2023).

Cardiac hypertrophy is an ideal model for mechanistic studies due to its well-defined cellular and molecular hallmarks: increased cardiomyocyte size, sarcomere reorganization, and reactivation of fetal gene programs. Subtypes include physiological (exercise-induced) and pathological (pressure overload, genetic) hypertrophy. Public datasets from the GTEx and ENCODE projects provide transcriptomic and epigenomic data. Open questions include the role of non-coding RNAs, metabolic reprogramming, and the transition from hypertrophy to heart failure.

The following pathways are central to the pathogenesis of cardiac hypertrophy:

1. G protein-coupled receptor (GPCR) signaling: Angiotensin II and endothelin-1 activate Gq/11, leading to phospholipase C (PLC) activation and inositol trisphosphate (IP3) production.

1. IP3 releases calcium from the sarcoplasmic reticulum, activating calcineurin and NFAT transcription factors.

2. NFAT translocates to the nucleus and induces hypertrophic gene expression.

2. MAPK/ERK pathway: Growth factors (e.g., IGF-1) and mechanical stretch activate Ras, Raf, MEK, and ERK1/2.

1. ERK phosphorylates transcription factors such as Elk-1 and c-Myc.

2. This leads to increased protein synthesis and cell growth.

3. PI3K/AKT/mTOR pathway: Insulin and IGF-1 activate PI3K, producing PIP3, which recruits AKT.

1. AKT activates mTORC1, promoting protein synthesis and cell growth.

2. AKT also inhibits GSK-3beta, reducing beta-catenin degradation and enhancing transcription.

4. Calcium/calmodulin-dependent kinase II (CaMKII) signaling: Increased intracellular calcium activates CaMKII, which phosphorylates histone deacetylases (HDACs).

1. Phosphorylated HDACs are exported from the nucleus, allowing MEF2 transcription factors to activate hypertrophic genes.

The following table summarizes high-frequency genetic alterations associated with cardiac hypertrophy, based on data from ClinVar, NCBI Gene, and COSMIC.

Data sources: ClinVar (2024), COSMIC (v99), NCBI Gene (2024).

Key deregulated signaling networks in cardiac hypertrophy include:

• • Wnt/beta-catenin pathway: Activation leads to beta-catenin nuclear translocation and transcription of hypertrophic genes (e.g., c-Myc, cyclin D1).
• • MAPK/ERK pathway: Sustained activation promotes cell growth and fibrosis.
• • PI3K/AKT/mTOR pathway: Hyperactivation drives protein synthesis and inhibits autophagy.
• • JAK/STAT pathway: Cytokine signaling (e.g., IL-6) activates STAT3, which induces fetal gene expression.
• • NF-kB pathway: Inflammatory signals activate NF-kB, promoting cytokine production and fibrosis.
• • Key nodes:
• • Beta-catenin (CTNNB1)
• • ERK1/2 (MAPK3/MAPK1)
• • AKT (AKT1)
• • STAT3
• • NF-kB (RELA)

The following table lists commonly used cell lines for cardiac hypertrophy research.

Organoids: 3D cardiac organoids derived from iPSCs or primary cells recapitulate tissue-level hypertrophy, including fibrosis and electrophysiological changes. They are advantageous for studying cell-cell interactions and drug responses in a more physiological context.

Common animal models for cardiac hypertrophy include:

• • Transverse aortic constriction (TAC) in mice: Induces pressure overload hypertrophy.
• • Angiotensin II infusion: Causes hypertension and hypertrophy.
• • Genetic mouse models: MYH7 R403Q knock-in, MYBPC3 knockout.
• • Rat models: Spontaneously hypertensive rats (SHR).
• • Zebrafish models: For high-throughput genetic screens.

CRISPR/Cas9 technology enables the creation of isogenic cell lines with precise genetic modifications. For cardiac hypertrophy, key models include:

• • MYH7 R403Q knock-in: Mimics a common hypertrophic cardiomyopathy mutation.
• • MYBPC3 knockout: Models sarcomere dysfunction.
• • GATA4 knockout: Studies transcription factor roles.
• • TNNT2 R92Q knock-in: Models altered troponin function.

These sequence-verified, commercially available models accelerate research by providing consistent, reproducible systems for mechanistic studies and drug screening. They eliminate the variability of transient transfections and allow for long-term experiments.

CRISPR knockout and knock-in lines are used to validate the role of specific genes in hypertrophy. For example:

• • GATA4 knockout in AC16 cells reduces hypertrophic gene expression (e.g., ANP, BNP) upon phenylephrine stimulation.
• • MYH7 R403Q knock-in in iPSC-CMs shows increased cell size and sarcomere disarray, confirming the mutation's pathogenicity.
• • TNNT2 R92Q knock-in in H9c2 cells alters calcium handling and contractility.

Isogenic pairs (e.g., wild-type vs. MYH7 R403Q) are used in drug screening to identify compounds that reverse hypertrophy. For example:

• • Screening for inhibitors of the calcineurin-NFAT pathway in MYH7 mutant cells.
• • Testing beta-blockers and calcium channel blockers in isogenic lines to assess differential efficacy.
• • Modeling resistance to standard therapies (e.g., ACE inhibitors) by introducing mutations in target genes.

CRISPR-based synthetic lethality screens identify genes that are essential only in hypertrophic cells. For example:

• • DepMap data (2024) shows that MYH7 mutant cells are sensitive to knockdown of sarcomere assembly genes (e.g., TTN, ACTC1).
• • Genome-wide CRISPR screens in hypertrophic iPSC-CMs can identify novel therapeutic targets and biomarkers (e.g., circulating microRNAs).

The following table lists key public databases for cardiac hypertrophy research.